اعلان هااااااااااااااام


Translate

Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer (Ipsen SA)

Monday, December 10, 2012

WN.com - Environment News
Latest headlines from WN Network
Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer (Ipsen SA)
Dec 10th 2012, 07:40

(Source: Ipsen SA) PRESS RELEASE Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer  Full recruitment triggers a €10 million milestone payment to Active Biotech Lund (Sweden) and Paris (France), December 10, 2012, Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol. This achievement triggers a €10 million milestone payment from Ipsen to Active Biotech. This study is a global,...
You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 Responses to Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer (Ipsen SA)

Post a Comment